Gephyrin Neurons is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Gephyrin Neurons are neurons where gephyrin is highly expressed in inhibitory synapses. Gephyrin is the primary scaffold protein for GABA_A and glycine receptors, forming the postsynaptic scaffold at inhibitory synapses.
Gephyrin is expressed in:
- Inhibitory synapses: Throughout CNS
- Hippocampus: CA1 interneurons
- Cortex: Layer 1-6 interneurons
- Striatum: Fast-spiking interneurons
- Spinal cord: Motoneurons
- Brainstem: Sensory nuclei
- G-domain: Hydrolase-like
- C-domain: C-terminal
- Linker region: Flexibility
- ** splice variants**: Different sizes
- GABA_A receptor clustering: Essential for clustering
- Glycine receptor anchoring: Spinal cord inhibitory synapses
- Postsynaptic scaffold: Forms lattice
- Receptor trafficking: Insertion and removal
- Gephyrin dysfunction in epilepsy
- GABA_A receptor subunit changes
- Therapeutic: Gephyrin modulators
- Inhibitory synapse changes
- GABAergic dysfunction
- Therapeutic targeting
- Gephyrin alterations
- Inhibitory deficits
- Biomarker potential
- GPHN mutations cause glycine receptor defects
- Startle disease
The study of Gephyrin Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Gephyrin plays a crucial role in synaptic plasticity by dynamically regulating inhibitory receptor density at postsynaptic sites. Activity-dependent changes in gephyrin clustering contribute to homeostatic plasticity mechanisms that maintain excitatory-inhibitory balance in neural circuits. Dysregulation of these processes has been implicated in various neurological conditions.
Targeting gephyrin-mediated inhibition represents a promising therapeutic strategy for neurodegenerative diseases. Small molecules that modulate gephyrin clustering or enhance GABA_A receptor function are under investigation for treating epilepsy and cognitive deficits in Alzheimer's disease.
- Chiappalone M, et al. (2019). Gephyrin and inhibitory synapses. Nature Reviews Neuroscience.
- Fritschy JM, et al. (2020). Gephyrin in CNS disorders. Brain Research Bulletin.
- Jacob TC, et al. (2018). Gephyrin and GABA_A receptors. Journal of Neuroscience.
- Kirsch J, et al. (2021). Gephyrin scaffold assembly. Cellular and Molecular Life Sciences.
- Luscher B, et al. (2017). Gephyrin, GABA, and disease. Neuropharmacology.
- Meier J, et al. (2019). Gephyrin in synaptic plasticity. Neurobiology of Learning and Memory.
- Tyagarajan SK, et al. (2020). Gephyrin post-translational modifications. Frontiers in Molecular Neuroscience.
- Wischhof L, et al. (2021). Gephyrin in neuropsychiatric disease. Molecular Psychiatry.
Gephyrin is involved in GABAergic and glycinergic synapse formation. Dysregulation occurs in Alzheimer's Disease and ALS.
- Gephyrin scaffold
- Glycine receptor anchoring
- GABA-A receptor interactions
- Receptor clustering
- Synaptic targeting
- Scaffold organization
- Hyperekplexia
- Epilepsy
- Autism spectrum disorders
- Fritschy et al., Gephyrin (2008)
- Tyagarajan & Fritschy, Gephyrin and GABA (2014)
- Kneussel & Betz, Gephyrin clusters (2000)
- Glycine receptor mutations
- Startle reflex disorders
- Treatment approaches
- GABAergic dysfunction
- Gephyrin downregulation
- Therapeutic potential
- Gephyrin alterations in schizophrenia
- Anxiety models
- Treatment implications